Dry Eye Disease Epidemiology Forecast Research 2020-2034: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dry Eye Disease - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of Dry Eye Disease (DED), historical and forecasted epidemiology of Dry Eye Disease (DED) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

For the purpose of designing the patient-based model for the Dry Eye Disease (DED) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of DED, Gender-specific Diagnosed Prevalent Cases of DED, Age-specific Diagnosed Prevalent Cases of DED, and Severity-specific Diagnosed Prevalent Cases of DED in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

In the assessment done, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54.69 million in 2023. Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of DED with ~6,112 thousand cases, followed by Germany, which had diagnosed prevalent population of ~5,004 thousand in 2023. On the other hand, Spain had the lowest prevalent population (2,064 thousand cases).

The US reported the highest number of total diagnosed prevalent cases of DED among the 7MM countries with 41% whereas Japan reported the least cases (19%). This trend is anticipated to be followed during the forecast period as well. In the US, gender-specific diagnosed prevalent cases of DED revealed ~9,439 thousand cases among males and approximately ~13,035 thousand cases among females. Projections indicate that by 2034, the prevalence among females will surpass that of males.

The analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ~4,889 thousand cases. This was followed by ~691 thousand cases in the 40-49 age group and ~532 thousand cases in the 18-39 age group. Projections indicate that the UK is expected to continue leading in these figures by 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Harvard Medical School, Boston, Massachusetts, US University of Pikeville, Kentucky College of Optometry, Pikeville, Kentucky, US; Magdeburg-Stendal University of Applied Sciences, Stendal, Sachsen-Anhalt, Germany; Department of Ophthalmology, Dijon University Hospital, Dijon, France; University of Milan, Milan, Italy; Optometry and Vision Science, Aston University, Birmingham, UK and Ryogoku Eye Clinic, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Key Highlights

• In 2023, the total diagnosed prevalence of Dry eye disease (DED) was highest in the US among the 7MM, accounting for nearly 22.47 million cases which is further expected to increase by 2034.
• In Japan, in 2023, ~2,341 thousand males and ~ 8.29 million females were affected with Dry eye disease (DED). estimates that these numbers might increase by 2034.
• In 2023, the UK reported ~2,811 thousand mild, ~1,345 thousand moderate, and ~1,956 thousand severe cases of DED. Analysis by experts indicates that the overall severity-specific cases of DED are expected to rise in the coming years.
• The Dry Eye Disease (DED) cases are expanding due to increasing prevalence, rising awareness and better diagnostic capabilities, which increase demand for treatments. Advancements in research, increased funding for rare diseases, and the development of novel therapies are also key drivers.
• As per estimates, Japan accounted for nearly 19% of the Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM in 2023.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Dry Eye Disease (DED), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Dry Eye Disease (DED) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of DED
• Gender-specific Diagnosed Prevalent Cases of DED
• Age-specific Diagnosed Prevalent Cases of DED
• Severity-specific Diagnosed Prevalent Cases of DED

Dry Eye Disease (DED) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Dry Eye Disease (DED) Epidemiology Segmentation

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Dry Eye Disease (DED) Epidemiology Overview at a Glance

3.1. Patient Share Distribution of DED in 2020

3.2. Patient Share Distribution of DED in 2034

4. Epidemiology Methodology of DED

5. Executive Summary of Dry Eye Disease (DED)

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Tear Film Working

7.3. Etiology

7.4. Risk Factors

7.5. Pathophysiology

7.6. Symptoms and Clinical Presentations

7.7. Diagnosis

7.7.1. Diagnostic Criteria

7.7.1.1. Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II

7.7.1.2. Diagnostic Criteria of the JDES, 1995 Version

7.7.1.3. Diagnostic criteria of DED proposed by the JDES (2006 version)

7.7.2. Differential Diagnosis

7.7.3. Diagnostic Algorithm

7.7.4. Diagnostic Scheme

7.7.5. Diagnostic Guidelines

7.7.5.1. Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: The 7MM

8.2.1. Diagnosed Prevalence of DED

8.2.2. Gender-specific Prevalence of DED

8.2.3. Age-specific Diagnosed Prevalence of DED

8.2.4. Severity-specific Diagnosed Prevalence of DED

8.3. Total Diagnosed Prevalent Cases of DED in the 7MM

8.4. The United States

8.5. EU4 and the UK

8.5.1. Germany

8.5.2. France

8.5.3. Italy

8.5.4. Spain

8.5.5. The United Kingdom

8.6. Japan

9. Patient Journey

10. KOL Views

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/vegs1w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.